

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 02186)

**MAJOR TRANSACTION REGARDING THE ACQUISITION OF EQUITY
INTEREST IN BEIJING JIALIN PHARMACEUTICAL CO., LTD.**

**EXTENSION OF LONG STOP DATE
AND
DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement of Luye Pharma Group Ltd. (the “**Company**”) dated 27 August 2014 regarding the acquisition of equity interest in Beijing Jialin Pharmaceutical Co., Ltd. (the “**Announcement**”). Unless otherwise stated herein, capitalised terms used in this announcement have the same meanings as those defined in the Announcement.

On 6 October 2014, the Purchaser, Mylin Holdings and the Target entered into a supplemental agreement to the First Tranche Agreement pursuant to which the parties agreed to extend the Long-stop Date to 20 November 2014. Save as disclosed above, all other terms and conditions of the Agreements remain the same.

Further, as set out in the Announcement, the Circular (together with the notice of the special general meeting and the proxy form) was expected to be despatched to the Shareholders on or around 8 October 2014. As the Company is still finalising the contents of the Circular, the Company expects to despatch the Circular to the Shareholders on or before 25 October 2014.

Shareholders and potential investors should note that Completion is subject to conditions precedent to be fulfilled and the Contemplated Acquisition is subject to negotiations by the parties. The Acquisitions and the Contemplated Acquisition may or may not proceed as contemplated or at all. Shareholders and potential investors should also note that there are risks associated with the Acquisitions and the Contemplated Acquisition and they should consider and assess all the risks carefully. Shareholders and potential investors are reminded to exercise extreme caution when dealing in the Shares and other securities of the Company.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 6 October 2014

As at the date of this announcement, the Executive Directors of the Company are Mr. LIU Dian Bo, Mr. YUAN Hui Xian, Mr. YANG Rong Bing and Ms. ZHU Yuan Yuan; the Non-executive Directors are Mr. PAN Jian, Mr. LIU Dong and Ms. WANG Xin; and the Independent Non-executive Directors are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.